Jazz Pharmaceuticals plc Overview
Jazz Pharmaceuticals plc (JAZZ) has a P/E ratio of 15.84, below the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow15.84
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for JAZZ is 15.84. That is below the Healthcare sector average of 25.3. Investors often review this figure alongside Jazz Pharmaceuticals plc's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, JAZZ currently prints 15.84 for P/E ratio, while the sector average sits near 25.3. That is roughly 37.4% below the sector mean. Large gaps often invite a closer look at Jazz Pharmaceuticals plc's growth, margins, and balance sheet.
A P/E ratio of 15.84 for Jazz Pharmaceuticals plc is not 'good' or 'bad' on its own. Compare it with the peer average (25.3) and with JAZZ's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting JAZZ's P/E ratio (15.84), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Jazz Pharmaceuticals plc's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
